Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase I trial to study the effectiveness of combining oblimersen with cytarabine and
daunorubicin in treating older patients who have previously untreated acute myeloid leukemia.
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop
growing or die. Oblimersen may help cytarabine and daunorubicin kill more cancer cells by
making them more sensitive to chemotherapy.